Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by You-Take Oh
Overcoming Acquired Resistance to AZD9291, a Third Generation EGFR Inhibitor, Through Modulation of MEK/ERK-dependent Bim and McL-1 Degradation
Clinical Cancer Research
Cancer Research
Oncology
Analysis of Cyclin-Dependent Kinase 2-Regulated Phosphorylation of Stathmin in Etoposide-Induced Apoptotic HeLa Cells by Two-Dimensional Electrophoresis and Mass Spectrometry
JOURNAL OF HEALTH SCIENCE
Related publications
MET or NRAS Amplification Is an Acquired Resistance Mechanism to the Third-Generation EGFR Inhibitor Naquotinib
Scientific Reports
Multidisciplinary
Molecular Mechanisms of Acquired Resistance to Third-Generation EGFR-TKIs in EGFR T790m-Mutant Lung Cancer
Annals of Oncology
Medicine
Oncology
Hematology
Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M
Nature Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
MA15.06 Circulating Tumor DNA Portrays the Resistance Landscape to a Novel Third Generation EGFR Inhibitor, AC0010
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
WZ4002, a Third-Generation EGFR Inhibitor, Can Overcome Anoikis Resistance in EGFR-mutant Lung Adenocarcinomas More Efficiently Than SRC Inhibitors
Laboratory Investigation
Forensic Medicine
Pathology
Cell Biology
Molecular Biology
NDRG2 Contributes to Cisplatin Sensitivity Through Modulation of BAK-to-Mcl-1 Ratio
Cell Death and Disease
Molecular Neuroscience
Immunology
Cell Biology
Cancer Research
Cellular
Medicine
PAK Signaling Promotes Acquired Resistance to BRAF and MEK Inhibitors
Cancer Discovery
Oncology
RASSF1A Mediates P21Cip1/Waf1-Dependent Cell Cycle Arrest and Senescence Through Modulation of the Raf-Mek-Erk Pathway and Inhibition of Akt
Cancer Research
Cancer Research
Oncology
Phenylethyl Isothiocyanate Reverses Cisplatin Resistance in Biliary Tract Cancer Cells via Glutathionylation-Dependent Degradation of McL-1
Oncotarget
Oncology
